Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUDARA vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
B-cell chronic lymphocytic leukemia (CLL) in adults who have not responded to or have progressed during treatment with at least one standard alkylating-agent regimen,Off-label: non-Hodgkin lymphoma, acute myeloid leukemia, conditioning for hematopoietic stem cell transplantation
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Fludarabine is dephosphorylated in serum to 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), which is then phosphorylated intracellularly to active triphosphate (F-ara-ATP). Further metabolism involves deamination by adenosine deaminase, but the primary route is renal excretion of unchanged drug and metabolites.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Fludarabine: 19-29% (primarily albumin); 2-fluoro-ara-A: minimal binding.
Approximately 85-90% bound to serum albumin.
Vd: 2.4 L/kg (fludarabine); 0.5-0.9 L/kg (2-fluoro-ara-A, approximating total body water).
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 55-75% under fasting conditions; food reduces Cmax but not AUC.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Cr Cl 30-70 m L/min: reduce dose by 20%. Cr Cl <30 m L/min: contraindicated.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No specific recommendations for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh C).
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Not established for pediatric patients; safety and efficacy not determined.
Not established; safety and efficacy not determined in pediatric patients.
No specific adjustment; monitor renal function and hematologic parameters closely.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: FLUDARA MAY CAUSE SEVERE BONE MARROW SUPPRESSION (ANEMIA, THROMBOCYTOPENIA, NEUTROPENIA) AND MAY INDUCE AUTOIMMUNE HEMOLYTIC ANEMIA. PATIENTS SHOULD BE MONITORED CLOSELY FOR HEMATOLOGIC TOXICITY. NEUROTOXICITY (INCLUDING BLINDNESS, COMA, AND DEATH) HAS BEEN REPORTED, PARTICULARLY AT HIGH DOSES (>40 mg/m2/day).
None.
Severe bone marrow suppression, particularly thrombocytopenia, anemia, and neutropenia,Autoimmune hemolytic anemia, which can be fatal,Neurotoxicity, especially at high doses; monitor for altered mental status, visual disturbances, seizures,Tumor lysis syndrome, especially in patients with high tumor burden,Immunosuppression and increased risk of opportunistic infections,Pulmonary toxicity including interstitial pneumonitis,Hepatotoxicity and increased liver enzymes,Use with caution in renal impairment; dose adjustment required (Cr Cl <30 m L/min)
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to fludarabine or any component of the formulation,Severe renal impairment (Cr Cl <30 m L/min) unless benefit outweighs risk,Pregnancy (can cause fetal harm),Lactation (discontinue nursing or drug)
Hypersensitivity to AURLUMYN or any of its components.
No specific dietary restrictions. Maintain adequate hydration. Grapefruit juice may interact; avoid excessive consumption. Avoid alcohol due to possible hepatotoxicity.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital malformations, particularly neural tube defects, craniofacial anomalies, and limb defects. Second and third trimester exposure can cause fetal growth restriction, myelosuppression, and increased risk of fetal death. Both animal studies and human case reports confirm significant fetal harm.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data exist on fludarabine excretion into human breast milk. Given its mechanism of action (DNA synthesis inhibitor) and potential for severe adverse effects (e.g., myelosuppression, carcinogenesis) in a nursing infant, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is unknown.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established dose adjustments exist for fludarabine during pregnancy. Due to increased plasma volume, renal clearance, and altered pharmacokinetics in pregnancy, standard dosing may result in subtherapeutic levels. However, given the high teratogenic risk, use is contraindicated; if unavoidable (e.g., life-threatening maternal condition), consider therapeutic drug monitoring and dose individualization based on AUC, but data are extremely limited and safety cannot be assured.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Fludarabine is a purine analog used in B-cell chronic lymphocytic leukemia (CLL). It requires dose adjustment in renal impairment (Cr Cl <30 m L/min). Myelosuppression is dose-limiting; monitor blood counts. Use with caution in patients with prior autoimmune hemolytic anemia. Trimethoprim-sulfamethoxazole should be given for Pneumocystis jirovecii prophylaxis. Allopurinol is recommended for tumor lysis syndrome prevention. Administer IV over 30 minutes or longer.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take this medication exactly as prescribed by your doctor.,You will need regular blood tests to monitor your blood cell counts.,Avoid live vaccines during treatment and for 12 months after.,Report any signs of infection (fever, chills, sore throat) or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 6 months after the last dose.,Drink plenty of fluids to help prevent kidney problems.,Avoid exposure to people with infections.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
"Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor, enhances intracellular cyclic AMP levels, leading to suppression of pro-inflammatory cytokine production and modulation of immune cell function. Fludarabine, a purine analog used in hematologic malignancies, exerts immunosuppressive effects through inhibition of DNA synthesis and lymphocyte apoptosis. Concurrent use may result in additive or synergistic immunosuppression, increasing the risk of severe infections, including opportunistic infections, and potentially delaying immune recovery in patients already immunocompromised due to fludarabine therapy."
"The combination of tacrolimus and fludarabine may increase the risk of toxicity, particularly nephrotoxicity and neurotoxicity, due to additive immunosuppressive effects and potential pharmacokinetic interactions. Fludarabine may inhibit the metabolism of tacrolimus through CYP3A4 competition, leading to elevated tacrolimus levels and increased adverse effects, including renal impairment and neurological symptoms such as tremors and seizures. Close monitoring is required to avoid severe outcomes like opportunistic infections and organ damage."
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUDARA vs AURLUMYN, answered by our medical review team.
FLUDARA is a Antineoplastic Agent that works by Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUDARA and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUDARA is: 25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUDARA and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUDARA is classified as Category C. Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital . AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.